ACN Newswire
HONG KONG, Feb 19, 2025 – (ACN Newswire) – Goldman Sachs’ latest report on China’s biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon®, which was recently included in China’s National Reimbursement Drug List (NRDL…
Read More
Goldman Sachs Raises Everest Medicines’ Target Price to HK$48.32 on Stronger Commercial and R&D Outlook
Arden Byron
03:21
HONG KONG, Feb 19, 2025 – (ACN Newswire) – Goldman Sachs’ latest report on China’s biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon®, which was recently included in China’s National Reimbursement Drug List
